CAPSULE
mediated down regulation of its levels substantially suppressed BI-induced SMC migration and proliferation resulting in reduced neointima formation. These novel findings suggest that PKN1 plays a critical role in vascular wall remodeling and, therefore, it could be a promising new target for the next generation of drugs for vascular diseases, particularly restenosis following angioplasty, stent implantation or vein grafting.
Restenosis, characterized by thickening of the arterial wall, is believed to be a multifactorial disease that occurs as a response to injury (1) . Among many cell types, smooth muscle cells have been shown to contribute profoundly to the pathogenesis of this vascular disease (2) . In addition in recent years, many reports showed that progenitor cell recruitment to, and homing at the site of vascular injury play a role in this disease pathogenesis (3) . A variety of biomolecules produced at the site of vascular injury appear to be involved in the pathogenesis of restenosis (2) . Among the many molecules identified, the artery produces monocyte chemotactic protein-1 (MCP-1) very acutely and robustly in response to injury (4) . MCP-1 also known as chemokine (C-C motif) ligand 2 (CCL2) belongs to CC chemokine family and it recruits monocytes, memory T cells and dendritic cells to the sites of tissue injury, infection and inflammation (5, 6) , Although some controversy exists in regard to the role of MCP-1 in VSMC mitogenesis previously (7), emerging evidence points out that it plays a major role in vascular 2 inflammation and possess the capacity to stimulate VSMC growth and thereby contribute to vascular wall remodeling (8-10). Earlier, we have reported that 15-lipoxygenase 1-15(S)-hydroxyeicosatetraenoic acid (15-Lox1-15(S)-HETE) axis induces the expression of MCP-1 via a mechanism involving epidermal growth factor receptor, Src, Jak2 and STAT-3 in intact artery in response to injury and mediate SMC migration leading to neointima formation (11, 12) . NFATs comprising of NFATc1-c4 and NFAT5 are members of a multigene family of transcriptional factors that belong to Rel group (13). Structure and function studies have identified a transcription activation domain (TAD) in the N-terminal region of NFATs (13). NFATc1 to NFATc4 contain a conserved serine-repeat regulatory region adjacent to TAD. This region also includes the calcineurin binding sites. The C-terminal region contains a Rel homology domain (RHD) that mediates NFAT DNA binding (13). Dephosphorylation of NFATs, which is mediated by a Ca 2+ /calmodulin-dependent phosphatase, calcineurin, leads to their activation and nuclear translocation (14) . On the other hand, phosphorylation by kinases such as glycogen synthase kinase 3β (GSK3β) invokes their nuclear export and inactivation (15). NFATs bind to GGAAA core DNA element present in the promoter regions of the genes and influence their transcription. In addition to their role in cytokine gene regulation in immune cells, a number of studies using knockout mice models have revealed that these transcriptional factors play an important role in the development of cardiovascular system as well as in the pathological cardiac hypertrophy (16-19). The work from our laboratory showed that these transcriptional factors are involved in the regulation of VSMC growth and migration (20, 21) . The most exciting findings in this aspect are our recent observations that the blockade of NFATs inhibits balloon injury-induced VSMC migration, proliferation and neointima formation (22) . In understanding the mechanisms of NFAT involvement in vascular wall remodeling, we found that NFATc1 targets cyclins, particularly cycin D1 and cyclin A2 in modulating both VSMC growth and migration (23, 24) . Thus, these findings provide strong evidence for the role of NFATs in receptor tyrosine kinase (RTK) and G protein-coupled receptor (GPCR) agonistinduced VSMC growth and migration in vitro and injury-induced neointima formation in vivo. However, targeting these transcriptional factors for drug discovery needs more extensive work to find whether they play a unifying role in the regulation of VSMC growth and motility in response to many cues. The present work was undertaken to test whether NFATs mediate the effects of MCP-1 in vascular wall remodeling and, if so, to identify the underlying mechanisms. . AntiKi67 (ab15580) and anti-pSer/Thr (ab17464) antibodies were purchased from Abcam (Cambridge, MA). Anti-cyclin D1 antibody (RB-010-P) was bought from NeoMarkers (Fremont, CA). Anti-NFATc1 antibody (MA3-024) was from Affinity BioReagents (Golden, CO). Anti-pPKN1 (2611) 
MATERIALS & METHODS

Adenoviral vectors:
The generation of pR1445 encoding human PKN1 catalytic domain (AA 560 to 950) with K644E mutation was described previously (25). To construct adenoviral vector, the mutant catalytic domain of PKN1 was amplified using the following primers:
forward, 5′-CTGGggtaccGTCGACATGGACAGCTCAC CTCAGAAG-3′ incorporating a KpnI restriction enzyme site at the 5'-end and reverse, 5′-CACCctcgagACTAGTGGATCCCCCGGGC TGCAGG-3′ incorporating a XhoI restriction enzyme site at the 5'-end and pR1445 as a template. The PCR products were digested with KpnI and XhoI and the released fragment was cloned into KpnI and XhoI sites of the pENTR3C vector (Invitrogen) to yield pENTR3C-dnPKN1 vector. The pAd-dnPKN1 was generated by recombination between pENTR3C-dnPKN1 and pAdCMVV5DEST (Invitrogen) and verified by DNA sequencing. The pAd-dnPKN1 was linearized with PacI and transfected into HEK293A cells. The resulting adenovirus was further amplified by infection of HEK293A cells and purified by cesium chloride gradient ultracentrifugation as described previously (22). Construction of Ad-GFP and Ad-GFPVIVIT was also described previously (22).
Cell culture: HASMCs were purchased from Cascade Biologicals (Portland, OR), subcultured in Medium 231 containing smooth muscle cell growth supplements and used between 4 and 10 passages.
Transfections and transductions:
HASMCs were transfected with siRNA molecules at a final concentration of 100 nM using Lipofectamine 2000 transfection reagent according to manufacturer's instructions. When adenoviral vectors were used to block the function of a specific molecule, cells were transduced with adenovirus harboring either GFP or dominant negative mutant of the target molecule at 40 moi overnight in complete medium. After transfections or transductions, cells were growth-arrested for 36 hrs and used as required.
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using its specific antibody as described previously (23). The band intensities were quantified using NIH Image J.
Common carotid artery balloon injury (BI):
All animal protocols were performed in accordance with the relevant guidelines and regulations approved by the Institutional Animal Care and Use Committee of the University of Tennessee Health Science Center, Memphis, TN. Sprague-dawley male rats weighing ~300g to 350g were used throughout the study. BI and adenoviral transductions were performed essentially as described previously (30). To deliver pharmacological PKN1 inhibitor, Ro318220, into the artery, it was prepared in DMSO, mixed with 30% pluronic gel and applied around the injured artery as described by Subramaniam et al (31). In the case of delivering siRNA molecules into the artery, control or targeting siRNA along with lipofectamine 2000 reagent were mixed in 30% pluronic gel and applied around the injured artery. At 1 day, 3 days, 5 days, 1 week or 2 weeks after BI, the animals were sacrificed by CO 2 inhalation followed by thoracotomy and the common carotid arteries were collected and processed for protein extraction and/or immunohistological staining.
In vivo smooth muscle cell migration assay:
The in vivo SMC migration was determined as described by Bendeck et al (32). Briefly, 3 days after BI, the carotid arteries were fixed in vivo with 10% buffered formalin at physiological pressure. The middle 1 cm of the denuded (injured) common carotid artery was cut and fixed in cold acetone for 10 min. The artery was then opened longitudinally and pinned down onto an agar plate with the luminal surface facing upward. The arteries were rinsed in PBS and then placed in 0.3% H 2 O 2 for 30 min to block endogenous peroxidase activity. Nonspecific protein binding was blocked by incubating the arteries in 5% normal goat serum in PBS for 30 min. The arteries were incubated with anti-SMCα-actin antibodies diluted 1:300 in PBS for 1 hr followed by incubation with biotinylated goat anti-mouse IgG for 30 min. Peroxidase labeling was carried out by using ABC kit (Vector Laboratories), and the signals were visualized by using DAB kit (Vector Laboratories). After each step, the slides were rinsed 3 times for 5 min each in PBS. Finally, the opened arteries were placed intimal side up on glass slides with coverslips. As a negative control, samples of the same specimens without the primary antibody incubation were used. The intimal surface of the vessel was examined under a light microscope at X200 magnification and SMCα-actin-positively stained cells were counted.
Double immunofluorescence staining:
Soon after isolation, the injured common carotid arteries were snap-frozen in OCT compound (Sakura Finetek USA Inc., Torrance, CA). Cryosections (5 µm) were made using Leica Kryostat (Model CM3050S, Leica, Wetzlar, Germany). After blocking in goat serum, the cryosections were incubated with rabbit antirat Ki67 antibodies and mouse anti-rat SMCα-actin antibodies for 1 hr. After washing in PBS, all slides were incubated with goat antirabbit secondary antibodies conjugated with Alexa Flour 568 and goat anti-mouse secondary antibodies conjugated with Alexa Flour 488. Fluorescence was observed under Zeiss Axio Observer Z1 Motorized Inverted microscope. Negative controls were processed exactly as described above except that they were not incubated with primary antibodies.
Histological staining: For morphometric analysis, the injured common carotid arteries were fixed in 10% formalin, dehydrated and embedded in OCT compound. The sections were made as described above and stained with Hematoxylin and Eosin. The intimal (I) and medial (M) areas were measured using NIH ImageJ and the I/M ratios were calculated. (Fig. 1A & B) . To test the role of NFATs in these responses, we first studied the effect of MCP-1 on NFATc1 activation in HASMCs. MCP-1 (50 ng/ml) induced NFATc1 stimulation as measured by its translocation from the cytoplasm to the nucleus in a time-dependent manner in HASMCs (Fig. 1C ) and cyclosporine A (CsA), a potent inhibitor of calcineurin (13), blocked MCP-1 induced NFATc1 translocation (Fig. 1D ). In addition, either blockade of NFAT activation by VIVIT, a pentapeptide that competes with NFATs for binding to calcineurin (33) or down regulation of NFATc1 levels using its siRNA attenuated MCP-1-induced HASMC DNA synthesis and migration ( Fig. 1E-H) . These results indicate that NFATc1 plays a role in MCP-1-induced DNA synthesis and migration.
Statistics
Both cyclin D1-dependent CDK4 and CDK6 activities are required for MCP-1-induced HASMC DNA synthesis and migration downstream to NFATc1: In our previous study, we demonstrated that NFATc1 mediates PDGF-BB-induced cyclin D1 expression (23). To test whether MCP-1 induces cyclin D1 expression, and if so, the role of NFATc1, we first studied the time course effect of MCP-1 on cyclin D1 expression. MCP-1 induced cyclin D1 expression in a time-dependent manner with maximum effect at 4 hrs and 8 hrs ( Fig. 2A) . Since cyclin D1 binds to CDK4-6 and form their respective holoenzymes, we next studied the time course effect of MCP-1 on CDK activities, particularly CDK4 and CDK6. Consistent with its effect on cyclin D1 expression, MCP-1 induced both CDK4 and CDK6 activities with maximum effects at 4 hrs 8 hrs (Fig. 2B) . Furthermore, down regulation of cyclin D1 levels by its siRNA inhibited MCP-1-induced CDK4 and CDK6 activities (Fig. 2C ). This finding indicates that cyclin D1 expression is needed for MCP-1-induced CDK4 and CDK6 activities. Using siRNA approach, next we examined their role in MCP-1-induced HASMC growth and migration. Down regulation of either cyclin D1 or CDK4/6 levels by their respective siRNA molecules blocked both MCP-1-induced HASMC DNA synthesis and migration ( Fig. 3A-D) . To understand the mechanisms by which MCP-1 induces cyclin D1 expression and CDK4/6 activities, we have studied the role of NFATs. Inhibition of NFAT activation by VIVIT or down regulation of NFATc1 levels by its siRNA suppressed MCP-1-induced cyclin D1 expression and CDK4/6 activities ( Fig. 4A-D) . These results suggest that NFATc1 mediates MCP-1-induced cyclin D1 expression and CDK4/6 activities in HASMCs.
MCP-1 induces PKN1 phosphorylation and activity in NFATc1 and cyclin D1-CDK6-dependent manner:
It was well established that Rho GTPases such as RhoA and Rac1 play an important role in cell migration and proliferation (34, 35). In addition, it was reported that these Rho GTPases regulate protein kinase N1 (PKN1) in mediating cytoskeleton organization (36, 37). Since, MCP-1 is a potent chemotactic protein, we wanted to find whether it has any effect on PKN1 activation. PKN1 activation requires phosphorylation at Thr774 (37). Therefore, we measured PKN1 Thr774 phosphorylation. To our surprise, MCP-1 induced the activation of PKN1 but not PKN2/3 in a time-dependent manner in HASMCs with maximum effect at 4 hrs and 8 6 hrs (Fig. 5A) . Furthermore, depletion of PKN1 levels by its siRNA blocked MCP-1-induced HASMC DNA synthesis and migration (Fig. 5B & C), suggesting that PKN1 plays an important role in MCP-1-induced HASMC growth and migration. To explore the mechanism of PKN1 activation by MCP-1, we have studied the role of NFATc1, cyclin D1 and CDK4/6. Depletion of NFATc1, cyclin D1 or CDK6 but not CDK4 levels abolished MCP-1 induced PKN1 phosphorylation ( Fig.  5D-F) .
To ascertain that PKN1 phosphorylation leads to its activation, we measured its kinase activity. MCP-1 induced PKN1 activity in a time-dependent manner ( Fig. 5G ). In addition, siRNA-mediated depletion of NFATc1, cyclin D1 or CDK6 levels blocked MCP-1-induced PKN1 activity (Fig. 5G ). To confirm the role of NFATc1, cyclin D1 and CDK6 in MCP-1-induced PKN1 activation, we also used siGENOME siRNA molecules, which are distinct from ON-TARGETplus SMARTpool siRNAs, to deplete their levels. Down regulation of NFATc1, cyclin D1 and CDK6 by their respective siGENOME siRNA molecules also attenuated MCP-1-induced PKN1 phosphorylation and activity (Fig. 5G ). Since cyclin D1-CDK6 modulated MCP-1-induced PKN1 activation, we next examined whether these molecules physically interact with each other by co-immunoprecipitation. We found that while CDK6 and PKN1 exist as a complex even in quiescent cells, cyclin D1 was found to be associated with this complex in an inducible manner in response to MCP-1 (Fig. 6A) . Similarly, increases in the association of pPKN1 and CDK6 with cyclin D1 were also observed in response to MCP-1 (Fig. 6A ). Since PKN1 was found to be associated with CDK6 and cyclin D1, we asked whether PKN1 is a substrate for CDK6. To address this question, quiescent HASMCs were treated with and without MCP-1 (50 ng/ml) for 8 hrs and cell extracts were prepared. An equal amount of protein from control and MCP-1-treated HASMCs was immunoprecipitated with anti-CDK6 antibodies and the immunocomplexes were subjected to immunocomplex kinase assay using recombinant full length PKN1 and [γ-32 P]-ATP as substrates. As shown in Fig. 6B , CDK6 phosphorylated PKN1 and this phosphorylation was found to be 2 to 3-fold more in response to MCP-1 treatment as compared to control. Together, these observations revealed that MCP-1 activates PKN1 in NFATc1-cyclin D1-CDK6-dependent manner mediating HASMC growth and migration.
PKN1
mediates BI-induced SMC migration, proliferation and neointima formation: To find whether arterial injury stimulates PKN1, if so, the potential role of NFATc1-cyclin D1-CDK6 axis, we used rat carotid artery restenosis model. We measured cyclin D1 expression, CDK6 activity and PKN1 phosphorylation/activity in carotid arteries at 1 day, 3 days and 5 days after vascular injury. BI induced cyclin D1 expression and CDK6 activity in a time-dependent manner with maximum effect at 3 days post injury (Fig.  7A ). BI also induced PKN1 phosphorylation and activity with maximum effects at 5 days post injury (Fig. 7A ). To test whether BIinduced PKN1 activation requires NFATcyclin D1-CDK6 axis, we studied the effect of VIVIT. Adenovirus-mediated transduction of VIVIT blocked BI induced cyclin D1 expression, CDK6 activity and PKN1 phosphorylation/activity (Fig. 7B) . To study the role of PKN1 in vascular wall remodeling, we examined the effect of Ro318220, a potent inhibitor of PKN1 (38), on BI-induced SMC migration, proliferation and neointima formation. Ro318220 blocked BI-induced SMC migration, proliferation and neointima formation ( Fig. 7C-E) . To confirm the role of PKN1 in vascular wall remodeling, we also used siRNA approach. Pluronic gel (30%, v/v)-mediated delivery of PKN1 siRNA (10 µg) mixed with Lipofectamine 2000 reagent into the artery depleted PKN1 levels substantially in the artery and attenuated BIinduced SMC migration, proliferation and neointima formation (Fig. 8A-D) . Similarly, adenovirus-mediated transduction of dnPKN1 also inhibited BI-induced SMC migration, proliferation and neointima formation (Fig.  9A-D) .
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DISCUSSION
The important findings of the present study are as follows: 1. MCP-1, a potent chemotactic protein, stimulated both growth and migration of HASMCs. 2. MCP-1 activated NFATc1 in a time-dependent manner in HASMCs. 3. Both MCP-1-induced HASMC growth and migration require NFATc1 activation. 4. MCP-1 induced cyclin D1 expression and CDK4/6 activities in NFATc1-dependent manner. 5. MCP-1-induced HASMC growth and migration require NFATc1-dependent cyclin D1 expression and CDK4/6 activities. 6. MCP-1 induced a sustained activation of PKN1 and this effect is mediated by NFATc1-cyclin D1-CDK6 activity. 8. PKN1 activation is needed for both MCP-1-induced HASMC growth and migration. 9. NFAT-mediated PKN1 activation is also required for BIinduced SMC migration, proliferation and neointima formation. Previously, we have reported that PDGF-BB and thrombin, the RTK and GPCR agonists, respectively, activate NFATc1 in exerting their effects on VSMC growth and migration (20, 21). In elucidating the mechanisms by which NFATc1 mediates VSMC growth and migration, we found that it enhances cyclin D1 expression at transcriptional level in HASMCs (23). In accordance with these observations, we also demonstrated that NFAT activation is required for injury-induced SMC migration, proliferation and neointima formation (22-24). Besides these reports, we found that MCP-1 is produced in endothelium-denuded artery and mediates injury-induced neointima formation (12). To find whether NFATc1 is a common effector transcriptional factor in mediating vascular wall remodeling in response to various cues, here we first examined the capacity of MCP-1 in the induction of HASMC growth and migration. MCP-1 induced both HASMC growth and migration. Next, we tested the effect of MCP-1 on NFATc1 activation. MCP-1 not only activated NFATc1 in HASMCs but its stimulation is required for the growth and migration of these cells in response to this chemokine. Another noteworthy observation is that like PDGF-BB, MCP-1 also induced cyclin D1 expression in NFATc1-dependent manner and the induction of cyclin D1 expression resulted in increased CDK4 and CDK6 activities. It was observed that both MCP-1-induced HASMC growth and migration exhibited a requirement for cyclin D1 expression and CDK4/6 activities. An established role of cyclin D1-CDK4/6 is their involvement in G1-S phase transition of a cell in response to a mitogen (39-41). But, in the present study we present evidence that cyclin D1 in concert with both CDK4 and CDK6 activities plays a role in MCP-1-induced HASMC growth as well as migration. While pRb phosphorylation is the major mechanism of cyclin D1-CDK4/6 role in cell cycle progression, the intricacies by which these cell cycle-dependent kinases modulate cell migration are less explored. In this aspect, it was reported that cyclin D1/CDK4 by binding to p27kip1 sequesters it away from the nucleus and promotes cell migration (42, 43). Additional studies have shown that cyclin D1-CDK4 via modulating the phosphorylation of filamin, an actin-binding protein, mediates cell migration (44). Thus, these studies point out that in addition to their conventional substrate, pRb, cyclin D1-CDK4-6 may phosphorylate many other molecules including cytoskeleton organization proteins and govern both cell proliferation and migration.
PKN1 is an effector molecule of RhoA/Rac1 and mediates cell migration by phosphorylating cytoskeleton organization proteins (45-47). Besides its role in the regulation of cell migration, two elegant studies in recent years have reported that PKN1 plays a major role in phosphorylationdependent demethylation of histone H3 and its involvement in chromatin remodeling and gene regulation downstream to androgen receptor activation (48, 49). In exploring the mechanisms by which NFATc1 mediates both VSMC proliferation and migration, we reported that it modulates cyclin D1 expression at transcriptional level and this in turn results in increased CDK4 activity (23). Towards elucidation of more downstream mechanisms, in the present study, as depicted in Figure 10 , we discovered that NFATc1 via enhancing the expression of cyclin D1 and 8 thereby modulating CDK6 activity mediates PKN1 phosphorylation/activation in a sustained manner in response to MCP-1. Since activation of PKN1 appears to be distal to NFATc1-cyclin D1-CDK6, it is more likely that PKN1 is involved in gene regulation downstream to NFATc1 mediating both cell proliferation and migration. One potential mechanism by which PKN1 may be involved in NFATc1-cyclin D1-CDK6-mediated gene regulation could be via phosphorylationdependent modifications of histones and their involvement in chromatin remodeling. This view also points out an additional role for NFATc1 in chromatin remodeling. Previously, some studies have reported that NFATs are involved in mediating angiogenesis (50, 51). However, the exact mechanisms by which NFATs are involved in angiogenesis are not clear. Based on the present findings, it may be speculated that NFATs, particularly, NFATc1 via targeting cyclin D1-CDK4/6 activities and thereby PKN1 phosphorylation/activation may be involved in the regulation of EC proliferation and migration, the two important events that are essential for angiogenesis.
The findings that BI induces cyclin D1 expression, CDK6 activity and PKN1 phosphorylation/activation in NFATdependent manner affirms that a signaling cascade that gets activated in response to a potent chemotactic protein, MCP-1, in HASMCs in vitro also occurs in intact artery in response to injury. Previously, we have reported that NFATs mediate BI-induced vascular wall remodeling. In addition, we showed that NFATs target cyclin D1 and thereby CDK4 activity in mediating BIinduced SMC migration and proliferation. In this report, we identify PKN1 as a new target molecule of NFAT-cyclin D1/CDK6 axis in mediating BI-induced SMC migration and proliferation, leading to enhanced neointima formation. Based on these observations, PKN1 could be a novel target for the drug development for cardiovascular diseases such as restenosis.
Ikeda, U., Okada, K., Ishikawa, S., Saito, T., Kasahara, T., and Shimada, K. Metzger, E., Imhof, A., Patel, D., Kahl, P., Hoffmeyer, K., Friedrichs, N., Muller, J. M., Greschik, H., Kirfel, J., Ji, S., Kunowska, N., Beisenherz-Huss, C., Gunther, T., Buettner, R., and Schule, R. Quiescent HASMCs were treated with and without the indicated doses of MCP-1 for 8 hrs and 24 hrs to measure cell migration and DNA synthesis, respectively. Cell migration was measured by Boyden chamber method and DNA synthesis was measured by [ 3 H]-thymidine incorporation. C. Quiescent HASMCs were treated with and without MCP-1 (50 ng/ml) for the indicated time periods and cytolplasmic and nuclear extracts were prepared. An equal amount of protein from control and each treatment was analyzed by Western blotting for NFATc1 levels using its specific antibodies. The blot was reprobed sequentially with anti-MEK1 and anti-p53 antibodies to show the relative purity of the cytoplasmic and nuclear extracts. D. Quiescent HASMCs were treated with and without MCP-1 (50 ng/ml) in the presence and absence of 10 µM CsA for 30 min, fixed, permeabilized and immunostained for NFATc1 using its specific antibodies followed by probing with Alexa Fluor 488-conjugated secondary antibodies. E & F. HASMCs that were transduced with either Ad-GFP or Ad-GFPVIVIT at 40 moi and quiesced were treated with and without MCP-1 (50 ng/ml) for either 24 hrs to determine DNA synthesis (E) or 8 hrs to measure cell migration (F). G & H. After transfection with control or NFATc1 siRNA (100 nM) and quiescence, HASMC DNA synthesis and migration were measured in response to MCP-1 as described in panels C and D, respectively. CE, cytoplasmic extract; NE, nuclear extract. *, p < 0.01 versus vehicle control, Ad-GFP or control siRNA; **, p < 0.01 versus Ad-GFP + MCP-1 or control siRNA + MCP-1. Quiescent HASMCs were treated with and without MCP-1 (50 ng/ml) for the indicated time periods and cell extracts were prepared. An equal amount of protein from control and each treatment was analyzed by Western blotting for cyclin D1 levels using its specific antibodies (A) or immunocomplex kinase assay for CDK4/6 activities using truncated recombinant retinoblastoma protein and [γ-
32 P]-ATP as substrates (B). The blot in panel A was reprobed with anti-β-tubulin antibodies to show the lane loading control. C. After transfecting with either control or cyclin D1 siRNA (100 nM) and quiescence, HASMCs were treated with and without MCP-1 (50 ng/ml) for 8 hrs, cell extracts were prepared and analyzed by immunocomplex kinase assay for CDK4/6 activities as described in panel B. Total cellular extracts containing an equal amount of protein from control and each treatment were analyzed by Western blotting sequentially for cyclin D1 and β-tubulin levels to show the effects of cyclin D1 siRNA on its target and non-target gene expressions. *, p < 0.01 versus vehicle control or control siRNA; **, p < 0.01 versus MCP-1 or control siRNA + MCP-1. HASMCs that were transduced with Ad-GFP or Ad-GFPVIVIT (40 moi) or transfected with control or NFATc1 siRNA (100 nM) were treated with and without MCP-1 (50 ng/ml) for 8 hrs and cell extracts were prepared and analyzed for cyclin D1 levels and CDK4/6 activities as described in Figure 2 , panels A and B, respectively. The blots in panels A and C were reprobed sequentially for GFP, β-tubulin or NFATc1 levels using their respective antibodies to show the expression of the vector, lane loading control or NFATc1 siRNA effect on its target and non-target gene expressions. The blots for GFP, β-tubulin or NFATc1 levels in panels B and D show the vector expression, normalization or NFAT siRNA on its target and non-target gene expressions in the total cell extracts. The bar graph in each panel represents the quantitative analysis of three independent experiments. *, p < 0.01 versus Ad-GFP or control siRNA; **, p < 0.01 versus Ad-GFP + MCP-1 or control siRNA + MCP-1. 
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extracts were prepared and analyzed by Western blotting for pPKN1 levels using its phosphospecific antibodies or immunoprecipitated with anti-PKN2 or anti-PKN3 antibodies followed by immunoblotting with pSer/Thr antibodies. B & C. HASMCs that were transfected with control or PKN1 siRNA (100 nM) and quiesced were subjected to MCP-1-induced DNA synthesis (B) and migration (C). D-F. HASMCs were transfected with control, cyclin D1, CDK4, CDK6 or NFATc1 siRNA (100 nM), quiesced, treated with and without MCP-1 (50 ng/ml) for 8 hrs and cell extracts were prepared and analyzed by Western blotting for pPKN1 levels using its specific antibodies. The blots in panels A, D, E and F were sequentially reprobed with anti-PKN1, anti-PKN2, anti-PKN3, anti-cyclin D1, anti-CDK4 or anti-CDK6 antibodies to show normalization, lane loading control or the effect of a specific siRNA on its target and non-target gene expression. G. Upper panel: An equal amount of protein from control and the indicated time periods of MCP-1 (50 ng/ml)-treated quiescent HASMCs were analyzed by immunocomplex kinase assay for PKN1 activity using MBP and [γ-
32 P]-ATP as substrates. Middle panel: HASMCs that were transfected with control, NFATc1, cyclin D1 or CDK6 siRNA (100 nM) and quiesced were treated with and without MCP-1 (50 ng/ml) for 8 hrs and cell extracts were prepared. Cell extracts containing an equal amount of protein from control and each treatment were analyzed for PKN1 activity as described in the upper panel. An equal amount of protein from the same cell extracts was also analyzed by Western blotting for pPKN1, PKN1, NFATc1, cyclin D1, CDK6 and β-tubulin levels using their specific antibodies to show the effect of the indicated siRNA on PKN1 phosphorylation as well as their target and non-target gene expression or normalization. Bottom panel: HASMCs that were transfected with control, NFATc1, cyclin D1 or CDK6 siGENOME siRNA (100 nM) and quiesced were treated with and without MCP-1 (50 ng/ml) for 8 hrs and cell extracts were prepared. Cell extracts containing an equal amount of protein from control and each treatment were analyzed by immunocomplex kinase assay for PKN1 activity and by Western blotting for pPKN1, PKN1, NFATc1, cyclin D1, CDK6 and β-tubulin levels as described in the middle panel. *, p < 0.01 versus vehicle control or control siRNA; **, p < 0.01 versus MCP-1 or control siRNA + MCP-1. Balloon injury induces PKN1 activation via NFAT-dependent manner and pharmacological inhibition of PKN1 suppresses BI-induced SMC migration, proliferation and neointima formation. A. Common carotid arteries were dissected out after the indicated time periods of BI and tissue extracts were prepared. The tissue extracts containing an equal amount of protein were analyzed for cyclin D1, pPKN1, PKN1 and β-tubulin levels by Western blotting using their specific antibodies or CDK6 and PKN1 activities by immunocomplex kinase assays. Recombinant retinoblastoma protein was used as a substrate for CDK6 assay and MBP was used as a substrate for PKN1 assay. B. Immediately following BI, arteries were transduced with Ad-GFP or Ad-GFPVIVIT at 10 10 pfu/ml. At 3 days post BI, arteries were dissected out and tissue extracts were prepared and analyzed for cyclin D1, pPKN1, PKN1, GFP and β-tubulin levels by Western blotting or CDK6 and PKN1 activities by immunocomplex kinase assays as described in panel A. C. At 3 days post BI and administration with vehicle or Ro318220 (10 µM) in 30% pluronic gel, the arteries were isolated, opened longitudinally and stained with anti-SMCα-actin antibodies. The SMCα-actin-positive cells were counted and SMC migration was expressed as the number of SMCα-actin-positive cells migrated onto a unit luminal surface area. The left side panel shows a representative picture of SMC migration onto the luminal surface and the bar graph in the right side represents the quantitative analysis of SMC migration from six animals. D. At 1 week post BI and exposure to vehicle or Ro318220 (10 µM) in 30% pluronic gel, the arteries were isolated, fixed, cryosections were made and stained for SMCα-actin and Ki67 using their specific antibodies. The upper panel shows the representative pictures of neointimal SMC proliferation and the lower bar graph shows the quantitative analysis of neointimal SMC proliferation from six animals. E. At 2 weeks post BI and exposure to vehicle or Ro318220 (10 µM) in 30% pluronic gel, the arteries were isolated, fixed, cross-sections made, 
